|
DGAP-News: MIG Verwaltungs AG
/ Key word(s): Regulatory Approval
MIG Fonds' portfolio company BioNTech receives first COVID-19 vaccine approval - private risk capital was crucial - First COVID-19 and mRNA vaccine worldwide - BNT162b2 - developed by BioNTech and its partner Pfizer was approved in the UK - MIG is a founding investor and long-term active shareholder of BioNTech - Development of BNT162b2 would not have been possible without risk capital from German private investors - MIG congratulates BioNTech and partner Pfizer, and is proud to be a part of this extraordinary achievement for Global Public Health - BioNTech confirms MIG's cross-sectoral tech focused investment strategy München, GERMANY, December 2, 2020 - MIG AG, the manager of MIG Fonds, a founding investor of BioNTech SE, today announces its portfolio company and its U.S. partner Pfizer Inc. have received the first approval of its COVID-19 vaccine BNT162b2, from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA). The emergency approval represents the first authorization of both a COVID-19 and mRNA vaccine ever. MIG, a German venture capital investment company focusing on life sciences and deep tech companies, congratulates BioNTech and its partners for successfully working together in this critical effort to support the Global Public Health system and billions of people. The development of this vaccine, and many other medicines combating serious diseases, was made possible with generous investments from both public and private institutions. MIG Fonds with its German and Austrian private investors, together with the strong commitment of the Strüngmann family office and other contributors, substantially supported the founding of BioNTech in 2008 and its growth strategy over the years including the Nasdaq IPO. "The world is a more hopeful place with today's approval of a vaccine to combat the SARS-CoV-2 pandemic. This success is a great example of private and public institutions working together to move the world forward. Here we see the value of the model where private investors and venture capitalists took the risk of investing in innovation at a very early stage of the company over many years, while pharma and public funding stepped in later on. With this approach, we can lay the foundation for future innovations offering more break-through solutions for mankind. At MIG, we are proud of having supported this achievement from the very beginning and feel encouraged to remain committed to investing in young and innovative companies in disruptive technology areas. Innovation needs risk capital," said Michael Motschmann, General Partner and Board Member of MIG. "BioNTech is also a great example of how technology and life sciences continue to grow together," Motschmann continues. "As the company successfully applies several deep technologies like machine learning, data analytics and automation & robotics for its biopharmaceutical developments, BioNTech represents an ideal investment case for MIG's cross-sectoral, technology- focused and long-term investment strategy." About MIG AG The MIG investment team is a committed group of engineers, biologists, scientists and investors who understand the importance of an analytical and creative approach to the opportunities Further information at , Contact: Media requests:
02.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
1152133 02.12.2020
